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Abstract
Background: The molecular chaperone, heat shock protein 90 (Hsp90) has been shown to be overexpressed in a
number of cancers, including prostate cancer, making it an important target for drug discovery. Unfortunately,
results with N-terminal inhibitors from initial clinical trials have been disappointing, as toxicity and resistance
resulting from induction of the heat shock response (HSR) has led to both scheduling and administration concerns.
Therefore, Hsp90 inhibitors that do not induce the heat shock response represent a promising new direction for
the treatment of prostate cancer. Herein, the development of a C-terminal Hsp90 inhibitor, KU174, is described,
which demonstrates anti-cancer activity in prostate cancer cells in the absence of a HSR and describe a novel
approach to characterize Hsp90 inhibition in cancer cells.
Methods: PC3-MM2 and LNCaP-LN3 cells were used in both direct and indirect in vitro Hsp90 inhibition assays
(DARTS, Surface Plasmon Resonance, co-immunoprecipitation, luciferase, Western blot, anti-proliferative, cytotoxicity
and size exclusion chromatography) to characterize the effects of KU174 in prostate cancer cells. Pilot in vivo
efficacy studies were also conducted with KU174 in PC3-MM2 xenograft studies.
Results: KU174 exhibits robust anti-proliferative and cytotoxic activity along with client protein degradation and
disruption of Hsp90 native complexes without induction of a HSR. Furthermore, KU174 demonstrates direct binding
to the Hsp90 protein and Hsp90 complexes in cancer cells. In addition, in pilot in-vivo proof-of-concept studies
KU174 demonstrates efficacy at 75 mg/kg in a PC3-MM2 rat tumor model.
Conclusions: Overall, these findings suggest C-terminal Hsp90 inhibitors have potential as therapeutic agents for
the treatment of prostate cancer.
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Background
Prostate cancer is generally recognized as a relatively
heterogeneous disease lacking strong biological evidence
to implicate specific oncogenesis, mutations, signaling
pathways, or risk factors in tumorigenesis and/or resis-
tance to therapy across patients. In 1952, Huggins and
Hodges first reported susceptibility of prostate cancer to
androgen withdrawal. Since that time, hormonal therapy
has become a mainstay for prostate cancer treatment;
however, despite dramatic initial clinical responses, vir-
tually all patients ultimately fail androgen-targeted abla-
tion. Experimental therapies in prostate cancer such as
targeted agents, immunotherapy, and vaccine therapy
exhibit limited efficacy and no improvement in survival
[1]. Thus, a critical need for novel therapies to treat
prostate cancer remains.
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One such approach is based on the development of
small molecules that inhibit Hsp90 chaperone function
which leads to the degradation of Hsp90 dependent
oncogenic proteins, many of which are involved in a
multitude of signaling cascades. Inhibitors of Hsp90
(Hsp90-I) effect numerous proteins and pathways that
are critical to the etiology of prostate cancer [2-4] and
have demonstrated significant anti-proliferative effects in
multiple cancer models, many of which are being evalu-
ated in clinical trials [5]. To date, most Hsp90-I are N-
terminal inhibitors. One example is the geldanamycin
derivative, 17-allylamino-17-demethoxygeldanamycin
(17-AAG). 17-AAG has demonstrated promising precli-
nical activity in-vitro and in-vivo [6-8]. Unfortunately,
like other N-terminal inhibitors, the efficacy of 17-AAG
is hampered by the fact that Hsp90 inhibition itself initi-
ates a heat shock response (HSR), ultimately resulting in
the induction of Hsp90 and anti-apoptotic proteins such
as Hsp70 and Hsp27 [9-11]. Furthermore, induction of
Hsp70 has been linked to chemoprotection [12-14]. In
fact, the largely cytostatic profile observed upon admin-
istration of 17-AAG across cancers is likely the result of
the pro-survival Hsp induction. This is supported by
studies showing that neutralizing Hsp72 and Hsp27
activity or their transcriptional inducer, HSF-1 augments
the effect of 17-AAG and dramatically increases the
extent of apoptosis [11,15,16]. Others have shown that
combinatorial approaches consisting of 17-AAG and
transcriptional inhibition of pro-survival Hsp’s improves
the efficacy of 17-AAG [17].
In contrast to N-terminal inhibitors, the coumarin
antibiotic novobiocin (NB) binds to the C-terminus of
Hsp90, inhibits its activity, but does not elicit a HSR
[18,19]. Previously the synthesis, screening and charac-
terization of NB analogues has been reported and have
demonstrated that molecules can be synthesized to exhi-
bit improved potency relative to NB [18,20,21]. Interest-
ingly, depending on the side-chain substitution of the
coumarin ring, these NB analogues can manifest potent
anti-proliferative and cytotoxic effects with minimal Hsp
induction or demonstrate neuroprotective effects in the
absence of cytotoxicity [18,19,22]. Herein, the distinct
biological activity of the second generation analog,
KU174 is described. KU174 demonstrates relative selec-
tive and rapid cytotoxicity (6 hr) along with client pro-
tein degradation in the absence of a HSR in hormone
dependent and independent prostate cancer cell lines.
Additionally, this work extends our understanding of
the biology and mechanism of C-terminal inhibition by
characterizing native chaperone complexes using Blue-
Native (BN) electrophoresis and size exclusion chroma-
tography (SEC). Under these native conditions, distinct
responses are observed to the Hsp90a, Hsp90b, and
GRP94 complexes following treatment with KU174
including the degradation of Hsp90b. Furthermore, the
direct binding of KU174 to recombinant Hsp90 is
described along with the functional inhibition of Hsp90
using a novel cell-based Hsp90-dependent luciferase
refolding assay. Finally, the in vivo efficacy and selective
tumor uptake of KU174 is reported in a pilot rat PC3-
MM2 xenograft tumor study.
Methods
NB analogues were synthesized as previously described
[23]. F-4, KU-174, NB and 17-AAG were dissolved in
DMSO and stored at -80°C until use. Commercial anti-
bodies were obtained for Hsp90 isoforms (a/b), Hsc70,
GRP94 (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA), Hsp27, Hsp70, HSF1, survivin, Akt, Caspase-3,
Her2/Erb2, HOP, Actin (Cell Signaling Technologies,
Danvers, MA), and Hsp60 (Epitomics, Inc., Burlingame,
CA).
Cell line acquisition and authentication
All cells were obtained from ATCC (Manassas, VA).
Prior to manuscript submission, genomic DNA from
frozen stocks of cell lines were submitted for short tan-
dem repeat analysis [24] at RADIL (University of Mis-
souri). Profiling results for each cell line were compared
to those listed on the ATCC website.
Cell culture
PC3-MM2-MM2 (androgen independent) and LNCaP-
LN3 (androgen dependent) prostate cancer cell-lines
[25] were obtained from M.D. Anderson Cancer Center
(Houston, TX) and cultured in MEM Eagle media
(Sigma-Aldrich, St. Louis, MO), respectively, with 10%
FBS and penicillin/streptomycin (100 IU/ml/100 mg/ml)
and maintained at 37°C with 5% CO2. Freeze downs
stocks of the original characterized cell-line were stored
under liquid nitrogen. All experiments were performed
using cells with < 20 passages and < three months in
continuous culture. Normal human renal proximal
tubule epithelial cells (RPTEC) were purchased from
Clonetics (Walkersville, MD) and grown per manufac-
turer instructions. RPTEC cells were not passaged more
than six times.
NCI Anti-proliferation Experiments of the NCI panel of 60
Cancer Cell lines
NCI60 tumor cell line screen was conducted by the
Developmental Therapeutics Program at NCI (http://
dtp.cancer.gov/) and was performed as previously
described [26]. Briefly, KU174 was run in a five concen-
tration dose response against the NCI panel of 60. From
dose response curves, growth inhibition of 50% (GI50)
was calculated from [(Ti-Tz)/(C-Tz)] × 100 = 50, which
is the drug concentration resulting in a 50% reduction
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in the net protein increase (as measured by SRB stain-
ing) in control cells during the drug incubation.
Annexin V apoptosis experiments
Cells were stained for Annexin V and propidium iodide
(PI) as previously described [18] and according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA).
The data displayed represented the mean SEM of three
independent experiments (n = 3).
Trypan blue cytotoxicity experiments
Cell viability was conducted as previously described [18].
Briefly, at the end of the incubation time for each cell
treatment group, non-adherent cells were collected and
combined with cells detached by trypsinization using
TrypLE™ Express (Invitrogen, Carlsbad, CA) followed
by centrifugation at 200 × g at 4°C. Cell pellet was then
re-suspended and washed twice with cold DPBS (Invi-
trogen, Carlsbad). Total cell counts and viability was
conducted on an automated system Vi-Cell™, Beckman
Coulter, Inc., Brea, CA).
Western blot
PC3-MM2 or LNCaP-LN3 cells were seeded at a den-
sity of 1.5 × 106 in T75 flasks. After 24 hours the T =
0 flask was harvested and cells counted by Vi-Cell.
Remaining flasks were dosed with drugs by serial dilu-
tion from DMSO stocks. Total cells after 24 hours
were pelleted and suspended into PBS. Suspended cells
were aliquoted for Vi-Cell cell viability measurements,
total protein SDS-PAGE analysis and Blue-native (BN)
electrophoresis. SDS-PAGE lysates were prepared in
RIPA (50 mM Tris-HCl pH 7.5, 150 mM, containing
0.1% SDS, 1% Igepal, 1% sodium deoxycholate, pro-
tease and phosphatase inhibitor cocktail, Sigma-
Aldrich, Inc., St. Louis, MO) and lysed by three freez-
ing and thawing cycles using liquid nitrogen and 37°C
water bath. Protein concentration was determined
using DC Protein Assay (Bio-Rad Laboratories, Her-
cules, CA) and a total of 25 μg of cell lysates were
used for Western blot.
Blue-native gel electrophoresis
BN lysates were prepared from PC3-MM2 or LNCaP-
LN3 cells in 20 mM Bis-Tris (pH 7.4), 125 mM
caproic acid, 20 mM KCl, 2 mM EDTA, 5 mM MgCl2,
10% glycerol and 2% n-dodecyl beta-D-maltoside
(DDM) followed by three freezing and thawing cycles
and centrifugation at 14,000 × g for 30 min at 4° C.
Protein concentration was determined as described
above and equal amounts of protein loaded on a
Native PAGE Novex 3-12% Bis-tris gel (Invitrogen,
Carlsbad, CA) and electrophoresed according to manu-
facturer’s instructions.
Size exclusion chromatography (SEC)
BN cells lysates, prepared as described above, were
injected onto a HiPrep 16/60 Sephacryl S-300 column.
SEC running buffer contained 20 mM Bis-Tris (pH 7.4),
125 mM caproic acid, 20 mM KCl, 2 mM EDTA, 5 mM
MgCl2, and 10% glycerol. Chromatography was per-
formed on an ATKAprime plus (GE Healthcare) at 0.5
mL/min and fractions (0.6 mL) were collected starting
at 31.5 mL. The column was calibrated with molecular
weight standards and the void volume determined with
blue dextran. In some experiments, individual fractions
from treated and untreated cells were concentrated
using Amicon 10K Ultra-0.5 (Millipore, Carrigtwohill,
Ireland) centrifugation filters and equal volumes were
analyzed by E-PAGE Western blot and probed as
described above.
DARTS assay
The Drug Affinity Responsive Target Stability (DARTS)
assay was optimized and used to assess protease protec-
tion from thermolysin as previously described [27,28].
KU174 was tested for protease protection using recom-
binant Hsp90a where a 25 μM concentration of each
drug was used to treat 1 μg of recombinant Hsp90a for
15 min on ice. Following drug treatment the samples
were digested with ~600U thermolysin for 10 min at
RT. The digestion reaction was stopped with 50 mM
EDTA and samples were analyzed by SDS-PAGE and
Western blot. In addition, the N-terminal inhibitors, 17-
AAG and radicicol, were used as positive controls along
with untreated and vehicle (DMSO) treated recombinant
Hsp90a.
Biotinylated KU-174 co-immunoprecipitation
Biotinylated KU-174 and KU-174 (-noviose) were pre-
pared by synthesis of their corresponding 3-(6-hydroxy-
3’-methoxy-[1,1’-biphenyl]-3-ylcarboxamido) derivatives
followed by biotinylation with NHS-PEG4-biotin in
DMF at room temperature in the presence of TEA. Bio-
tinylated compounds were isolated by RP-HPLC fol-
lowed by vacuum drying with structure confirmation by
mass spectrometry. A total of 1000 pmol of biotinylated
compound was added to 1 mg of PC3-MM2 native
lysates or 1 μg recombinant Hsp90 per reaction. In
some reactions binding was competed with excess ATP
using a regeneration system consisting of 2 mM ATP,
10 mM creatine phosphate disodium salt, 3.5 U/mL
creatine kinase and 0.6 U/mL inorganic pyrophospha-
tase. Samples were immunoprecipated at 4°C with con-
tinuous rotation for 4 - 16 hours followed by the
addition 50 μL of Dynabeads® M-280 Streptavidin mag-
netic beads (Invitrogen, Oslo, Norway). After 15 minute
incubation, beads were magnetically separated and pel-
lets washed 5X with wash buffer (PBS, 1% BSA, 0.1%
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DDM). Captured Hsp90 protein was released by boiling
samples with 50 μL SDS sample buffer. A total of 15 μL
was loaded on an e-PAGE gel (Invitrogen, Carlsbad,
CA) and probed for Hsp90 as described above.
Surface Plasma Resonance (SPR)
SPR analysis of KU174 binding to Hsp90b was purified
from baculovirus infected Sf9 cells and immobilized to
SensiQ SSOO COOH1 SPR sensor chips as described
previously [18,19]. KU174 (25 μl), diluted in assay buffer
containing 10 mM PIPES pH 7.4, 300 mM NaCl, and
2% DMSO was injected over the surface of the deriva-
tized chip at a flow rate of 25 μL/min at 25°C at the
indicated concentrations with binding measured with a
SensiQ SPR instrument (ICX Nomadics). Curves were
double referenced to subtract contributions of the buffer
containing 2% DMSO to the response units. QDAT
software (ICX Nomadics) was used to analyze the sen-
sorgrams for the kinetics of binding (ka) and dissociation
(kd) and the SPR binding curves to estimate the affinity
of binding (Kd).
Cancer cell based Hsp90 dependent luciferase refolding
assay
Luciferase refolding assay was performed in cells pre-
viously stably trandsduced with lenti virus carrying
Luc2/mCherry genes. Briefly, cell pelletes were collected
from 80-90% confluent flasks and resuspended in pre-
warmed media (50°C) for approximately 6 minutes. This
time and temperature was sufficient to denature the
endogenous luciferase to less than 2% of the basal activ-
ity but was insufficient to decrease viability of cells (data
not shown). Cells were then plated at a density of
50,000 cells/well in a 96 well white plate in the presence
of inhibitors. After one hour, the extent of refolded luci-
ferase was measured by the addition of a luciferin sub-
strate solution and read on a Victor III luminometer set
for 0.1 sec/well integration. Direct inhibtion of luciferase
was analysed for each compound as previously described
[29]. IC50 values were calculated from raw data plotted
or normalized to control using a non-linear regression
and sigmoidal dose response curves (GraphPad Prism).
In-vivo orthotopic tumor studies
Rat prostate xenograft tumor model single dose study
Eight week old nude rats (Crl:NIH-Foxn1rnu, Charles
River) were inoculated orthotopically with 1 × 106 PC3-
MM2 cancer cells. The rats were allowed to develop sig-
nificant tumor burden, approximately 60-70 days, after
inoculation. Subsequently, a single dose study of KU174
or vehicle was administered (i.p.) to treatment groups of
five rats and the animals were sacrificed by exsanguina-
tions six hours after injection. Immediately following
blood collection, the thoracic cavity was opened and the
animal was perfused exhaustively with saline. Tumors
were collected and tumor to plasma ratio determined by
standard bioanalytical methods.
Rat prostate xenograft tumor model efficacy study
Subsequent to the single dose study, an in-vivo efficacy
study with KU174 was conducted using NIH nude rats
inoculated subcutaneously in the flank with 2 × 106
PC3-MM2 cancer cells. Tumors developed for eight
days at which time twenty rats were randomized into
four treatment groups (vehicle, 15, 25, and 75 mg/kg
KU174). The average tumor volume between groups
was equal to ~30.13 mm3 using the formula L × W ×
H. Rats were to be dosed daily for 14 consecutive days
(day 0) and tumor volumes measured three times per
week. Following the third dose, one vehicle treated and
two KU174 treated (75 mg/kg dose), therefore the dos-
ing schedule was changed to every other day to allow 48
hours recovery between doses, in case this was a result
of toxicity. The 15 and 25 mg/kg groups continued on a
daily dosing schedule until the animals were sacrificed
on Day 17 while the vehicle and 75 mg/kg treatment
groups continued with doses every other day with the
study ending on Day 25 with no further mortality or
apparent gross toxicity. Data were analyzed as the med-
ian percent increase in tumor volume relative to the
initial tumor volume and tissues were sent to a veteri-
narian pathologist for toxicity analysis (Xenometrics,
Stillwell, KS). Animal experiments were carried out in
the animal facilities of The University of Kansas Medical
Center with strict adherence to the guidelines of the
IACUC Animal Welfare Committee of KUMC (IACUC
protocol # 2009-1837).
Results
KU174 exhibits broad activity across the NCI60 cancer cell
panel
Human tumor cell lines from the NCI60 panel were
used to assess KU174 activity across cancers. This
screen revealed that KU174 exhibits broad activity
across multiple cancer cell lines (Table 1). Notably
KU174 appears to be particularly active across the mela-
noma cell lines and was also cytotoxic in the multi-drug
resistant ovarian adenocarcinoma cell line (NCI/ADR-
RES). In the prostate cancer cell lines, PC-3 and DU145,
KU174 was cytostatic at the single dose of 10 μM with
values of 0.46 and 51.79, respectively. Furthermore, test-
ing of the LNCaP-LN3 androgen dependent prostate
cancer cell line in anti-proliferative assays demonstrate a
GI50 of 128 nM (data not shown). Based on previous
publications in prostate cancer using an earlier analogue,
F-4 [18], we chose to focus on the characterization of
KU174 in the PC3-MM2 and LNCaP-LN3 cell-lines to
further understand its mechanism of action and effects
on Hsp90.
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KU174 exhibits relatively specific cytotoxicity, to cancer
cells compared to normal renal cells
KU174 induced cytotoxicity in prostate cancer cells was
assessed by trypan blue exclusion. PC3-MM2 (Figure 1)
cells dosed with KU174 for 24 hours exhibited a dose-
dependent decrease in viability ranging from 70-25%
(Figure 1A, left panel). The parent compound NB, at
500 μM, resulted in a viability of ~75%; indicating
KU174 manifests a 10-50 fold increase in potency com-
pared to its parent molecule. No loss in cell viability
was observed with 17-AAG at 10 μM which is consis-
tent with previously published data demonstrating no
cytotoxicity in either cell line at concentrations as high
as 100 μM [18]. Comparing total cells to the time zero
cell density revealed that 0.1 μM KU174 is as cytostatic
as 10 μM 17-AAG (Figure 1A, right panel). These data
show that KU174 is cytostatic at low relative concentra-
tions (0.1 - 1 μM) and cytotoxic at higher concentra-
tions (10 - 50 μM). In the LNCaP-LN3 cell line, the
same trend was observed with respect to cytotoxicity
with KU174 being approximately three to five fold more
potent (data not shown). Furthermore, PC3-MM2 cells
dosed with KU174 for only six hours (Figure 1B, left
panel) resulted in a similar cytotoxic response as
observed at 24 hours. Conversely, normal human renal
proximal tubule epithelial cells (RPTEC) dosed with
KU174 for 6 hours (Figure 1B, right panel) exhibited no
loss in viability, providing evidence that KU174 is
relatively selective for both prostate cancer cell lines.
The RPTEC was selected as the normal cell line based
on previous studies that Hsp90 inhibitors have a 100-
fold lower affinity in normal cell lines compared to
tumor cell lines [30].
Following 24 hour KU174 treatment, approximately
25-50% of the cells remain viable in the 10-50 μM range.
Thus, the mode of cytotoxicity was examined between 24
and 48 hours of treatment by flow cytometry. PC3-MM2
cells were gated into four quadrants, identifying: viable
(I), necrotic (II), early apoptotic (III), and late apoptotic
(IV) cells. Figure 1C shows that KU174 treatment elicits
two modes of action by inducing mostly necrosis within
24 hours as evidence by the cytotoxicity data above with
little staining in quadrants III and IV. Furthermore, sig-
nificant late stage apoptosis was observed on the remain-
ing cells between 24 and 48 hours in a time and dose-
dependent manner as evidence of the increase in number
of cells in quadrant IV. Surprisingly, a majority of cells
appeared in the late apoptotic quadrant (IV) with signifi-
cantly fewer cells in the early apoptosis and necrosis
quadrants (III, and II, respectively, Figure 1C, bar
graphs). Likewise, a significant trend was observed in the
LNCaP-LN3 cell line indicating these data are not unique
to a single cell line (data not shown). These data demon-
strate KU174 necrotic cytotoxicity between 6-24 hours
and that cells remaining after the 24-hour treatment
undergo dose-dependent apoptosis.
Table 1 KU-174 Activity Across NCI-60 Human Tumor Cell Lines
Leukemia Renal Cancer Melanoma Colon Cancer
CCRF-CEM 0.63 786-0 73.59 LOX-IMVI 9.59 COLO-205 0.63
HL-60(TB) 0.44 A498 83.68 MALME-3M 41.99 HCC-2998 42.97
K-562 23.12 ACHN 47.1 M14 -21.95 HCT-116 21.97
MOLT-4 -21.98 CAKI-1 71.91 MDA-MB-435 -17.38 HCT-15 32.2
RPMI-8226 -44.19 RXF-393 105.66 SK-MEL-2 41.67 HT29 66.64
SR 28.61 SN12C 63.5 SK-MEL-28 21.39 KM12 -45.47
TK-10 14.99 SK-MEL-5 -73.95 SW-620 38.13
UO-31 18.75 UACC-257 -39.68
UACC-62 -27.18
NSC-Lung Cancer CNS Cancer Ovarian Cancer Breast Cancer
A549/ATCC 4.66 SF-268 43.3 IGROV1 28.24 MCF7 5.74
EKVX 66.17 SF-295 43.01 OVCAR-3 14 MDA-MB-231 81.66
HOP-62 0.11 SF-539 77.23 OVCAR-4 1.21 HS-578T 51.84
NCI-H23 -21.22 SNB-19 72.87 OVCAR-5 103.07 BT-549 24.27
NCI-H322M 69.89 SNB-75 81.1 OVCAR-8 -13.39 T-47D -27.58
NCI-H460 25.82 U251 38.81 NCI/ADR-RES -5.97 MDA-MB-468 9.61
NCI-H522 2.5 SK-OV-3 98.1
Prostate Cancer
PC-3 0.46
DU-145 51.79
NOTE: The numbers reported are from a single dose (10 μM) study and are displayed as growth relative to the no-drug control after 24 hours. Values between 0
and less than 100 indicate growth inhibition whereas values less than 0 (negative values) indicate cytotoxicity.
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Figure 1 KU174 mediated induction of selective cytotoxicity and apoptosis in PC3-MM2 prostate cancer cells. Selective cytotoxicity was
determined by trypan blue exclusion assay in PC3-MM2 cells (Figure 1A and 1B, left panel) at 24 and six hours, respectively. Normal RPTEC cells
dosed for six hours did not show a loss of viability (Figure 1B, right panel). Furthermore, total PC3-MM2 cells (Figure 1A, right panel) were
counted following 24 hours of treatment and compared to the number of cells plated at time zero (T = 0) demonstrating potent anti-
proliferation of KU174 as low as 100 nanomolar. Further cytotoxicity studies were conducted by flow where viable cells (quadrant I) were
compared to cells undergoing necrosis (quadrant II), early apoptosis (quadrant III) or late-stage apoptosis (quadrant IV) by measuring the percent
Annexin V and propidium iodide (PI) staining of the parent population for PC3-MM2 cells (Scatterplots Figure 1C) following KU174 treatment. A
bar graph of these data along with statistical analysis is shown (Figure 1C, right panel). Columns depict the mean ± SEM from three independent
experiments (n = 3), * and ** indicates significant paired t-test P value of < 0.05 and < 0.01 respectively, compared to vehicle-treated control.
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KU174 results in a dose-dependent decrease in client
proteins without a concomitant increase in Hsps
A hallmark of Hsp90 inhibition is the selective degrada-
tion of Hsp90 dependent client proteins. Therefore, the
level of expression of Hsp90 client proteins that are
known to be associated with prostate cancer cell survival
was examined [2,31-35] in prostate cancer cell lines. The
potential of KU174 to trigger degradation of client pro-
teins, effect Hsp modulators (HOP and HSF-1) and the
assessment of heat shock protein induction were ana-
lyzed in the PC3-MM2 (Figure 2A-B) and LNCaP-LN3
(Figure 2C) following 24 hours of treatment. In both
cancer cell-lines, KU174 demonstrated a dose-dependent
reduction in Hsp (Hsc70 and Hsp27), HSF-1 and client
proteins (survivin Akt, Her2, nestin, CXCR4 and cas-
pase-3) whereas, a minimal effect was seen on these
proteins in normal RPTEC cells (data not shown). Con-
versely, a modest induction of the ER chaperone,
GRP94, and the mitochondrial chaperone, Hsp60 was
observed with KU174 treatment (Figure 2), while no
changes were observed in the expression of glucose-
related protein 78 (GRP78)/Bip (data not shown).
Importantly, KU174 at concentrations of five times
higher than 17-AAG did not induce a significant heat
shock response. Conversely, the N-terminal inhibitor
17-AAG caused a robust heat shock response inducing
pro-survival Hsp70 and Hsp27 proteins in PC3-MM2
cells. Interestingly, since KU174 causes cytotoxicity as
early as six hours, it can be hypothesized that client pro-
tein should correspondingly be degraded at this time
point. In both prostate cancer cell lines, client protein
degradation was observed which supports Hsp90 inhibi-
tion as the mechanism of cell death (Figure 2D).
Analysis of native chaperone complexes by Blue Native-
PAGE (BN-PAGE) and Size Exclusion Chromatography
(SEC)
Hsp90 functions as part of a large multiprotein complex
and therefore, inhibition of Hsp90 may lead to disrup-
tion of these complexes. In order to study this process
BN-PAGE Western blot studies were performed that
allowed to the characterization of native chaperone
complexes. In these studies, a robust disruption of an
Hsp90|3 specific complex (Figure 3A) was observed,
while NB, 17-AAG, and F-4 (a less potent early novo-
biocin analog) only moderately disrupted the complex.
Furthermore, KU174’s effect on various other native
chaperone complexes was assessed; including Hsp90a,
Hsp90b, GRP94 and Hsc70. These complexes resolved
at a relative MW of 400 kDa for Hsp90a and Hsp90b,
while GRP94 complexes migrated near 720 kDa and 242
kDa with Hsc70 resolving mainly as a monomer under
these native conditions (Figure 3B). Differential disrup-
tion of Hsp90a and Hsp90b complexes was observed
with C-terminal Hsp90 inhibitors, NB and KU174 (Fig-
ure 3B) with little to no effect by the N-terminal inhibi-
tor 17-AAG. A drug-dependent increase in GRP94
complexes along with a decrease in HscHsc70 monomer
and complex was observed with KU174 but not with
17-AAG. A potential criticism of the data in Figure 3A-
B is that these complexes are a product of in-vitro cul-
ture conditions and not physiologically relevant. To
address this issue, two prostate cancer patient samples
were analyzed along with the corresponding normal
adjacent tissue and the mitochondrial chaperone Hsp60
was used as a loading control. These results yielded
similar Hsp90 native complexes compared to those
observed in the PC3-MM2 cell-line (Figure 3C). Similar
results were also observed with the androgen dependent
cell line LNCaP-LN3, however these cells were generally
more sensitive to KU174 in terms of dissociating the
native Hsp90 complexes (Figure 3D). To further investi-
gate these complexes, native Hsp complexes were frac-
tionated by SEC and analyzed by SDS-PAGE Western
blot. Chaperone complexes were identified containing
Hsp90b, Hsp90a, and GRP94, all of which appeared to
shift in MW following KU174 (25 μM) treatment com-
pared to vehicle treated cells (Figure 4A). With respect
to Hsp90a and Hsp90b, these observations, taken in
context with the apparent disruption of the ~400 kDa
complex observed in BN Western blots (Figure 3B), sug-
gests that these higher MW complexes were unable to
enter the BN gel or did not resolve into distinct bands
and therefore gave the impression in BN gels of a
decreased complex at 400 kDa. Significant Hsps were
also detected in the column void volume (fractions 7-
12). Interestingly, Hsp90b eluted within the void volume
and showed degradation that was not observed in the
Hsp90a blot, raising the potential that Hsp90b is
degraded in situ with bound client proteins. Addition-
ally, Figure 4A demonstrates that the co-chaperones
HOP and Hsc70 co-elute within the void volume (frac-
tion 10) in vehicle but not with KU174 treated samples
providing evidence that KU174 disrupts the binding or
stability of these co-chaperones in complex with Hsp90.
The functionality of these higher MW chaperone com-
plexes was further assessed by subjecting the native frac-
tions to a novel luciferase refolding assay adapted from
the widely used rabbit reticulocyte assay developed by
Matts and colleagues [29]. PC3-MM2 cells dosed with
vehicle or 0.1 μM KU174 for 24 hours were lysed and
fractions 9-16 collected by SEC. The chaperone activity
from the pooled fractions of each sample was tested as
a function of luciferase refolding as described in Materi-
als and Methods. Vehicle fractions 9-16 showed lucifer-
ase refolding activity which could be inhibited in a dose-
dependent manner by KU174 (Figure 4B). Furthermore,
cells treated with 0.1 μM KU174 for 24 hours showed a
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Figure 2 Selective KU174 mediated client protein degradation in the absence of heat shock protein induction. PC3-MM2 (Figure 2A and
2B) and LNCaP (Figure 2C) were examined for client protein degradation and the induction of heat shock proteins. 17-AAG demonstrates Hsp
induction (Figure 2A) in PC3-MM2 while KU174 triggers degradation of Hsc70, HspHsp27 and HSF-1 with induction of GRP94 and HspHsp60 in
PC3-MM2 cells. Notably, KU174 induced a dose-dependent decrease in several known proteins (Akt, Her2, nestin and CRCX4) that have been
shown to play a role in the etiology of prostate cancer. A similar trend of client protein degradation was seen in LNCaP however this cell line
was generally more sensitive to inhibitors (Figure 2C). Rapid client protein degradation within 6 hours was seen in both cell lines (Figure 2D).
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decrease in activity by approximately 50% compared to
vehicle (Figure 4C). The refolding activity for both vehi-
cle and treated fractions was further inhibited in a dose-
dependent manner with novobiocin. These data suggest
that Hsp90 complexes eluted within SEC fractions 9-16
are active and retain chaperoning ability as measured by
their refolding of thermally denatured luciferase.
DARTS Assay of KU174 binding to Hsp90
Binding of a drug/ligand to its target protein results in
conformational changes and proteolytic stabilization of
the protein by reducing sensitivity to proteases
[27,36,37]. Similar in concept to DNase protection assay
[38-40], or protease protection assay, Drug Affinity
Responsive Target Stability (DARTS) [27,28] was used
Figure 3 Analysis of native Hsp90 complexes in PC3-MM2 and LNCaP cells by Blue Native Western blot and identification of the
Hsp90 complex from human tissue. Native Hsp90 complexes were identified by Native Western blot (Figure 3A). 17-AAG, novobiocin and F-4,
an early novobiocin analog, had little effect on the Hsp90b complex. Conversely, cytotoxic concentrations of KU174 resulted in potent disruption
of the Hsp90b complex (Figure 3A). Dose-dependent effects on Hsp90b, Hsp90a, GRP94 and Hsc70 native complexes were determined
following treatment of cells KU174 along with novobiocin and 17-AAG (Figure 3B). Hsp90b complex was also observed in human cancer tissue
from two patient samples but to a lesser extent in their normal adjacent tissue (Figure 3C). Hsp60 served as a loading control showing relative
equal loading across the patient samples. KU174 also exhibits activity in the androgen dependent cell line LNCaP resulting in Hsp90 complex
disruption (Figure 3D).
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to test the specificity of KU174 for Hsp90. Recombinant
Hsp90 was incubated with 25 μM of KU174, 17-AAG,
radicicol or vehicle, followed by digestion with thermo-
lysin and analysis by SDS-PAGE Western blot for pro-
tection of Hsp90 protein. KU174 along with the known
Hsp90 N-terminal inhibitors, 17-AAG and radicicol,
protected Hsp90 from degradation as evident by the
upper band (Figure 5A) that is apparent in the control
(no thermolysin lane), but absent in the vehicle treated
lane that received thermolysin. These data demonstrate
the direct binding of KU174 to Hsp90.
Co-immunoprecipitation of biotinylated KU174 and Hsp90
In order to further support that KU174 binds Hsp90,
biotinylated KU174, along with an inactive analogue
lacking a critical noviose sugar, was used in co-immuno-
precipitation experiments. Using PC3-MM2 cell lysates
in the presence or absence of ATP (Figure 5B), biotiny-
lated KU174 (b-KU174) but not the inactive analogue
(-noviose) bound with sufficient affinity to
immunoprecipitate Hsp90 and that binding is prevented
with excess ATP. While it is unclear whether the ATP
is competing directly at the C-terminal site or is acting
allosterically by binding to the N-terminus and thus pre-
venting accessibility at the C-terminal pocket, this data
demonstrates that KU174 is binding directly to Hsp90.
Surface Plasma Resonance (SPR)
In order to further characterize KU174 as a direct
Hsp90 inhibitor, the binding of KU174 to Hsp90 was
analyzed by surface plasmon resonance (SPR) spectro-
scopy (Figure 5C). The kinetics of binding and dissocia-
tion were reliably fitted to a pseudo-first order model
for a 1:1 interaction with the ka and kd calculated to be
1.04 × 103 (M-1.sec-1) and 0.098 (sec-1), respectively. The
Kd estimated from the fitting of the binding curve (78
μM ± 7 s.e.) was in close agreement with the Kd esti-
mated from the ratio of the dissociation and association
constants (94 μM ± 4 s.e.). In comparison, the ka and kd
for the binding of novobiocin to Hsp90 were 211 (M-1.
Figure 4 Native Size Exclusion Chromatography (SEC) fractionation of Hsp90 complexes and inhibition of Hsp90 dependent luciferase
refolding activity. Vehicle or 25 μM KU174 treated (24h) SEC fractions were probed by SDS-PAGE Western blot. For each protein in Figure 4A, a
vehicle control treated (Figure 4A, panel C) and a KU174 treated (Figure 4A, panel T) are depicted. Pooled vehicle fractions (9-16) showed the
ability to refold thermally denatured luciferase and this activity was inhibited by KU174 (Figure 4B). In a follow-up study, PC3-MM2 cells treated
with or without KU174 (0.1 μM) were fractionated by SEC and fractions 9-16 of each sample were pooled and chaperone activity was tested as a
function of luciferase refolding (Figure 4C). The chaperone refolding activity of 0.1 μM KU174 treated samples is reduced to ~50% of vehicle (see
left axis segment) and was further inhibited by novobiocin. These data suggest KU174 directly inhibits Hsp90 complex refolding activity.
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sec-1) and 0.23 (sec-1) (calculated Kd of 1.1 mM ± 0.4 s.
e), with a Kd calculated from the binding curve of 0.86
mM ± 0.02 s.e.). Thus, the SPR analysis of the interac-
tion of KU174 with Hsp90 indicated the compound
bound directly to the purified recombinant protein with
an affinity approximately 12-fold higher than NB.
Cancer cell based Hsp90 dependent luciferase refolding
assay
Direct inhibition of the Hsp90 protein folding machin-
ery was assessed using a cancer cell-based luciferase
refolding assay developed in our laboratory. Previously,
the Hsp90 luciferase-based refolding assay has been
validated using rabbit reticulocyte lysates. However,
there remains concern whether the presentation of
Hsp90 complexes within these lysates are physiologi-
cally relevant in cancer. Several lines of evidence sug-
gest that Hsp90 is present in cancer cells as part of a
large macromolecular complex and therefore drugs
that target Hsp90 activity should be engineered
towards binding Hsp90 within its physiologically rele-
vant cancer cellular environment. Based on the afore-
mentioned limitations using rabbit reticulocyte lysates,
a cell-based luciferase assay was optimized using both
N-terminal and C-terminal Hsp90 inhibitors in pros-
tate cancer cell lines (Figure 6A-D). The extent of luci-
ferase refolding in PC3-MM2 in the presence of N-
terminal or C-terminal Hsp90 inhibitors was evaluated
at 60 and 90 minutes. Both classes of Hsp90 inhibitors
demonstrated similar EC50 concentrations at 60 and 90
minutes (Figure 6A) with 17-AAG being more potent.
Since a 60 minute refolding experiment resulted in a
significant increase in luciferase activity and good sig-
nal to noise, all subsequent experiments were per-
formed at this time point. In order to demonstrate
assay performance and accuracy, the parent compound
NB and an earlier, less potent analogue, F-4 was com-
pared to KU174 and 17AAG. As expected, NB and F-4
resulted in right shifted dose response curves relative
to KU174 with NB showing minimal activity (Figure
6B). Subsequently, a second N-terminal inhibitor, radi-
cicol, and an inactive novobiocin analog determined in
our laboratory to not bind Hsp90, KU298, were ana-
lyzed in this assay as additional positive and negative
controls, respectively. In this experiment, radicicol
demonstrated an EC50 value comparable to 17-AAG,
while as expected KU298 was inactive, further support-
ing the specificity of this assay for Hsp90 inhibition
(Figure 6C). Finally, to compare this assay across pros-
tate cancer cell lines, the ability of Hsp90 inhibitors to
inhibit luciferase refolding was examined in an
LNCaP-LN3 luciferase expressing cell line (Figure 6D).
In agreement with our previous results, these com-
pounds inhibited Hsp90 dependent luciferase refolding
with increased potency (EC50) when comparing EC50
values between cell lines, a trend that has also been
observed in other functional assays. Overall, these data
demonstrate a novel approach to determine on-target
Figure 5 Analysis of the binding of KU174 to Hsp90. Drug
Affinity Responsive Target Stability (DARTS) was used to test the
specificity of KU174 to Hsp90. Recombinant Hsp90 was incubated
with 25 μM of KU174, 17-AAG, radicicol or vehicle, followed by
digestion with thermolysin and analysis by SDS-PAGE Western blot
for protection of Hsp90 protein (Figure 5A). Upper band is
protected from proteolysis by both N-terminal and C-terminal
Hsp90 inhibitors. Biotinylated KU174 (b-KU174) but not the inactive
analogue (-noviose) bound with sufficient affinity to
immunoprecipitate Hsp90 in native PC3-MM2 cell lysates (Figure 5B).
Importantly, binding was prevented with excess ATP. KU174 was
injected over Hsp90b immobilized to the surface of a SPR sensor
chip at concentrations of 0.25, 0.5, 1.0, 10, 50, 100, and 200 μM as
described under “Materials and Methods”. Sensorgrams of KU174
binding to Hsp90b are shown (Figure 5C, left) and a concentration
dependent binding curve for the interaction of KU174 with Hsp90b
(Figure 5C, right).
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Figure 6 Cancer cell based Hsp90 dependent luciferase refolding assay. The extent of thermally denatured luciferase refolding in PC3-MM2
in the presence of N-terminal or C-terminal Hsp90 inhibitors was tested at 60 and 90 minutes (Figure 6A). The parent compound NB and an
earlier, less potent, analogue F-4, along with KU174 and 17AAG was subsequently tested for their ability to inhibit luciferase refolding over 60
minutes (Figure 6B). Next we compared a second N-terminal inhibitor, radicicol, and an inactive novobiocin analog, KU298, determined in our
laboratory to not bind Hsp90 as an additional positive and negative control for this assay, respectively (Figure 6C). Similar results were also seen
in the androgen dependent cell line LNCaP; however, 17AAG, radiciol and KU174 exhibited increased potency (Figure 6D).
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Hsp90 inhibition using a functional assay in an intact
cancer cell milieu.
In-vivo preclinical proof-of-concept studies
Initially, pilot pharmacokinetic (PK) studies of KU174
were conducted in the mouse (data not shown) and
revealed extensive metabolism and clearance preventing
the use of this species for efficacy studies as effective
concentrations of drug could not be achieved at the site
of action (tumor). Therefore, KU174 was initially tested
in the rat PC3-MM2 xenograft tumor model in a single
dose pilot PK study to ensure that effective concentra-
tions could be reached in the tumor prior to conducting
a multi-dose efficacy study. A KU174 tumor to plasma
ratio of 4:1 was achieved six hours after a single i.p.
administration of 75 mg/kg suggesting selective reten-
tion (Figure 7A). The concentration of KU174 in the
tumor correlated to ~17 μM, assuming a gram of tissue
is equal to one milliliter, at this time point, which was
believed to be sufficient enough to observe a pharmaco-
dynamic response based on our in vitro data. Following
this single dose study, a multi-dose efficacy study was
conducted using a rat PC3-MM2 xenograft tumor
model so that tumor volume could be monitored over
time. In this study, KU174 (15, 25, 75 mg/kg) was admi-
nistered by i.p. injection in tumor burden rats as
described in materials and methods. When the median
percent increase in tumor volume was analyzed relative
to the initial tumor volume, a consistent trend was evi-
dent and demonstrating a decrease in tumor size in the
75 mg/kg KU174 treated animals (p = 0.08, n = 4) (Fig-
ure 7B). Additionally, one animal was lost from the
vehicle and 75 mg/kg treatment group during the course
of the study. To rule out toxicity from either the vehicle
or KU174, major organs (liver, kidney, heart, lungs, and
prostate) were collected from all animals remaining at
the end of the study. The tissues were examined by a
veterinary pathologist for the presence of KU174
Figure 7 In-vivo efficacy and selective tumor accumulation of KU174 in rat prostate tumor models. Six hours following a single i.p. dose,
the tumor to plasma ratio of KU174 was determined to be ~3.6:1 suggesting selective tumor accumulation (Figure 7A, **p value < 0.01). Median
percent increase in tumor volume relative to the initial tumor size from a pilot study in a rat PC3-MM2 tumor xenograft dosed with KU174 (15,
25, and 75 mg/kg) Tumor growth inhibition was evident between vehicle (n = 4) and the 75 mg/kg group (** p = 0.08, n = 4) (Figure 7B).
Microscopic examination of kidneys from both vehicle (captisol) and 75 mg/kg KU174 treated animals showed prominent vacuolization
compared to untreated (Figure 7C) indicating captisol resulted in some degree of toxicity.
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toxicity. Treatment associated microscopic lesions were
noted in the heart, kidney, liver, and lung for both vehi-
cle and KU174 treated groups which was concluded to
result from vehicle. The severity of the morphological
changes by tissue were kidney > lung > liver > heart and
it was concluded these effects were caused by vehicle
administration. Microscopic examination of kidneys
from both vehicle (captisol) and 75 mg/kg KU174 trea-
ted animals showed prominent vacuolization compared
to untreated (Figure 7C). In summary, KU174 demon-
strates a significant reduction in tumor volume based on
this pilot study with no signs of apparent toxicity; how-
ever, there was evidence of acute vehicle toxicity which
was most evident in kidneys.
Discussion
Since 1995, when the first Hsp90 inhibitor was shown to
demonstrate antitumor efficacy in mouse xenograft
tumor models, there has been considerable effort focused
on the development of Hsp90 inhibitors for the treat-
ment of cancer. To date, there have been minor differ-
ences reported between N-terminal or C-terminal Hsp90
inhibitors. We recently reported that the novobiocin ana-
logue, F-4 induces client protein degradation with mini-
mal Hsp90 induction in androgen dependent and
independent prostate cancer cells [18]. These were some
of the first pieces of evidence that showed C-terminal
inhibitors to possess a unique pharmacology when com-
pared to N-terminal inhibitors. A hallmark of N-terminal
Hsp90 inhibition is the induction of Hsps (Hsp27, Hsp70
and to a lesser extent Hsp90) mediated through HSF-1
transcriptional activation of the heat shock response ele-
ment (HSE). This is of significant concern because clini-
cal resistance has been attributed to the induction of pro-
survival Hsps [11,41,42]. As a result, targeting Hsp70 and
Hsp27 has become an attractive paradigm for the preven-
tion of resistance with future Hsp90 inhibitors. Herein,
the development of a more potent C-terminal Hsp90
inhibitor, KU174 is described, which not only results in
client protein degradation in androgen dependent and
independent cell lines but also causes concomitant
reduction of Hsc70, Hsp27 and HSF-1 without Hsp70
induction. Notably, these client proteins, heat shock pro-
teins and Hsp90 modulators are all novel drug targets. In
addition, some client proteins (CXCR4 and survivin)
were degraded by KU174 but not 17-AAG suggesting
inhibition of the N-terminal and C-terminal sites effect
different subpopulations of proteins. Thus, KU174 elicits
a combinatorial attack on numerous drug targets in pros-
tate cancer cells resulting in potent cytotoxicity as early
as six hours that is relatively selective for tumor cells ver-
sus normal cells (Figure 1B).
The induction of GRP94 at the total protein level (Fig-
ure 2A) and with respect to native complexes (Figure
3D) was a surprising result. GRP94 up-regulation has
been associated with ER stress but is also correlated
with increased tumor immunogenicity [42]. Thus, the
significance of GRP94 induction with KU174 is unclear
and will require further investigation. To date, there has
been little focus on the different biological activities
manifested by Hsp90 inhibitors with regard to the
Hsp90a and Hsp90b isoforms and their respective
native complexes. In this study for the first time, we
reveal that a C-terminal Hsp90 inhibitor can induce a
major 400 kDa Hsp90 native complex into higher MW
supercomplex which seems to be relatively more selec-
tive for Hsp90b. Interestingly, the concentrations at
which this effect is observed corresponds nicely with
our cytotoxicity data (Figure 1A). Furthermore, KU174
induced Hsp90b degradation with no effect on Hsp90a
(Figure 4A), suggesting a possible isoform selective
response to chaperone inhibition. One hypothesis is that
the apparent KU174 induced shift to higher MW com-
plexes is a result of increased Hsp90 inhibited chaper-
one complexes containing unfolded client proteins.
Thus, it’s plausible that as unfolded client protein
becomes ubiquitinated, Hsp90b is collateral damage and
is degraded in-situ with its bound client protein. In sup-
port of this, recent preliminary data demonstrates the
induction of polyubiquitinated proteins that co-elute
with the partially degraded Hsp90b (data not shown).
Functionally, Hsp90 complexes isolated by SEC from
KU174 treated cells can refold denatured luciferase but
to a lesser extent compared to vehicle treated prostate
cancer cells. Although further characterization and func-
tional studies are required on the lower relative MW
SEC fractions, these data suggest that the large (>600
kDa) Hsp90 complex is a functional chaperone complex
and when inhibited by a C-terminal Hsp90 inhibitor
leads to the partial degradation of Hsp90b but not
Hsp90a (data not shown). Collectively, the direct bind-
ing of KU174 to recombinant Hsp90 is demonstrated
using DARTS, and SPR experiments as well as biotiny-
lated KU174 that co-immunoprecipitates Hsp90 from
tumor cell lysate, which can be eluted in an ATP-depen-
dent manner. Functionally, the inhibition of Hsp90 com-
plexes in tumor cell lysate and intact cancer cells is
shown using the Hsp90 dependent luciferase refolding
assay. Collectively, these data demonstrate direct on-tar-
get inhibition of Hsp90 at concentrations that correlate
to cytotoxicity, client protein degradation and disruption
of Hsp90 complexes by SEC and BN Western blot.
Pilot in vivo efficacy studies were conducted and while
there are limitations of this study, the results are
encouraging, especially in light of the rather aggressive
nature of PC3-MM2 tumors and the fact there has been
little success in establishing human prostate tumor
xenograft models in the rat. Collectively, these data
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demonstrate the in-vivo efficacy of KU174 in an aggres-
sive androgen independent prostate cancer cell-line. Lar-
ger in-vivo efficacy studies to determine more precisely
the effectiveness of KU174 in orthotopic and metastatic
PC3-MM2 tumor models in rat are currently being
designed.
Conclusions
In this study, the biological differences between the N
and C-terminal Hsp90 inhibitors, 17AAG and KU174,
are highlighted in prostate cancer cells. Most notably,
the C-terminal Hsp90 inhibitor, KU174, elicits its anti-
cancer activity without inducing a HSR, which is a detri-
ment associated with N-terminal inhibitors. Addition-
ally, a novel approach to examine inhibition of Hsp90
complexes was developed using BN Western blot, SEC
and luciferase refolding assays in intact cancer cells.
These new approaches, along with newer assays being
developed in our lab to address the issues of Hsp90 iso-
form specificity and selectivity, give us valuable mechan-
isms to investigate the development of future C-
terminal Hsp90 inhibitors. KU174 and other C-terminal
Hsp90 inhibitors are currently in early preclinical devel-
opment for a number of cancers, in addition to prostate.
We continue to focus on improving the potency and
pharmacokinetics of these compounds to further evalu-
ate in-vivo efficacy and identify a lead candidate for clin-
ical trials.
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